Adjuvant Therapy After Neoadjuvant Therapy for Esoph

Annals of Surgery

278, e240

DOI: 10.1097/sla.0000000000005679

Citation Report

#	Article	IF	Citations
1	Age-Dependent Benefit of Neoadjuvant Treatment in Adenocarcinoma of the Esophagus and Gastroesophageal Junction: A Multicenter Retrospective Observational Study of Young Versus Old Patients. International Journal of Surgery, 2023, 109, 3804.	7.0	14
2	Optimal Policy Tree to Assist in Adjuvant Therapy Decision-Making After Resection of Colorectal Liver Metastases. Surgery, 2024, 175, 645-653.	3.2	10
3	Postoperative Morbidity After Simultaneous Versus Staged Resection of Synchronous Colorectal Liver Metastases: Impact of Hepatic Tumor Burden. Surgery, 2024, 175, 432-440.	3.2	13
4	Recurrence Timing and Patterns Incorporating Lymph Node Status After Neoadjuvant Chemoradiotherapy Plus Esophagectomy for Esophageal Squamous Cell Carcinoma. Frontiers in Oncology, 2024, 14, 1310073.	3.5	3
5	Adjuvant Nivolumab in Esophageal Cancer With Positive Resection Margins: A Premature Leap?. Annals of Surgical Oncology, 2024, 31, 3567-3568.	3.3	0
6	Putting Wind in the Sails of Neoadjuvant Therapy for Locally Advanced Esophageal Adenocarcinoma: Perioperative Outcomes. Annals of Surgical Oncology, 2024, 31, 5495-5496.	3.3	0
7	The Patterns and Risk Factors for Relapse in Oesophageal Squamous Cell Cancers That Achieve Pathological Complete Response to Neoadjuvant Chemoradiotherapy. European Journal of Cardio-thoracic Surgery, 2024, .	2.2	9
8	Toward Precision in Critical Care Research: Methods for Observational and Interventional Studies. Critical Care Medicine, 2024, 52, 1439.	6.0	16
9	Is Postoperative Adjuvant Radiotherapy Necessary for Patients With Esophageal Cancer After Neoadjuvant Chemoradiotherapy?: An Analysis Based on the SEER Database. Journal of King Abdulaziz University, Islamic Economics, 2024, 45, 900-910.	2.1	2
10	A Narrative Review on Advances in Neoadjuvant Immunotherapy for Esophageal Cancer: Molecular Biomarkers and Future Directions. International Journal of Cancer, 2025, 156, 20-33.	5.0	13
11	Advancing Precision Oncology With Digital and Virtual Twins: A Scoping Review. Cancers, 2024, 16, 3817.	5.3	58
12	Current Status and Perspectives of Esophageal Cancer: A Comprehensive Review. Cancer Communications, 2025, 45, 281-331.	16.7	173
13	Adjuvant Treatment After Neoadjuvant Chemoradiotherapy and Surgery in Patients With Esophageal Squamous Cell Carcinoma: A Real-World Study. Therapeutic Advances in Medical Oncology, 2025, 17, 17588359251316179.	4.2	5
14	Multi-Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma. Cancer Medicine, 2025, 14, e70676.	3.8	6
15	Neoadjuvant Immunochemoradiation Therapy Versus Chemoradiation Therapy in Esophageal Cancer: A Systematic Review and Meta-Analysis of Reconstructed Individual Patient Data. International Journal of Radiation Oncology Biology Physics, 2025, 123, 483-494.	5.1	15
16	Clinical Efficacy and Biomarkers of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma. Cancer Immunology, Immunotherapy, 2025, 74, 243.	6.3	7
17	Real-World Applications of Postneoadjuvant Stage I of the Staging System for Oesophageal Squamous Cell Cancer: What Is Beyond a Pathological Complete Response?. European Journal of Cardio-thoracic Surgery, 2025, .	2.2	0
18	Incidence of MSI-H Esophageal Carcinoma and Related Identification of Genomic Alterations: A Multi-Center Real-World Study. Human Pathology, 2025, 163, 105878.	3.2	2

#	Article	IF	Citations
19	The Role of Pathological Response in Predicting the Benefit of Adjuvant Therapy After Neoadjuvant Chemoimmunotherapy in Patients With Esophageal Cancer. European Journal of Surgical Oncology, 2025, 51, 110360.	3.4	9
20	Comparative Study of Neoadjuvant Chemoradiotherapy, Chemotherapy, and Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. BMC Cancer, 2025, 25, 1-11.	4.3	2
21	Additional Treatment for Esophageal Cancer Patients With Incomplete Resection Due to the Surrounding Organ Invasion: A Nationwide Survey of 45 Japanese Centers. Esophagus, 2026, 23, 1-11.	2.9	0
22	Tumor Regression Grade as a Predictor of Adjuvant Therapy Benefits in Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Therapy. Cancer Medicine, 2025, 14, e71166.	3.8	5
23	Recurrence Patterns and Prognosis of Esophageal Cancer Patients Based on the Rbr Resection Status. Frontiers in Oncology, 2025, 15, 1615285.	3.5	0
24	Efficacy of Adjuvant Immunotherapy and Immunochemotherapy in Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study. International Journal of Cancer, 2026, 158, 1891-1904.	5.0	2
25	Neoadjuvant Chemoimmunotherapy for Elderly Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2026, 33, 1-12.	3.3	0
26	Effects of Postoperative Adjuvant Therapy on Prognosis for Esophageal Cancer Patients After Neoadjuvant Therapy Followed by Esophagectomy: A Systematic Review and Meta-Analysis. International Journal of Surgery, 2026, 112, 8491.	7.0	2
27	Development and Validation of a CT-Based Online Calculator for Prognosis and Postoperative Adjuvant Transcatheter Arterial Chemoembolization Benefit Prediction in Resected Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. International Journal of Surgery, 2026, 112, 7832.	7.0	3
28	A Pathological Classification for Predicting Recurrence and Guiding Adjuvant Therapy in Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy: A Two-Center Cohort Study. Frontiers in Oncology, 2026, 16, 1778731.	3.5	1
29	Transitioning From Neoadjuvant Chemoradiation to Perioperative Chemotherapy for Esophageal Adenocarcinoma: Impact on Margins and Pathologic Outcomes. JTCVS Open, 2026, 32, 101829.	2.0	0
30	Heterogeneity of Adjuvant Therapy Effectiveness Across Post-Neoadjuvant Pathologic Strata in Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study. Esophagus, 2026, 23, 1-15.	2.9	0
31	Adjuvant Immunotherapy Versus Observation After Neoadjuvant Therapy and Esophagectomy for Esophageal Cancer With Residual Pathologic Disease: A Systematic Review and Reconstructed Individual Participant Data Meta-Analysis. Frontiers in Immunology, 2026, 17, 1944032.	6.9	0